Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
04
2022
accepted:
05
07
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
Patients with rheumatoid arthritis (RA) have an increased risk of infections; therefore, immunization against vaccine-preventable diseases is important. Methotrexate (MTX) impairs the antibody response to pneumococcal conjugate vaccine (PCV) in patients with arthritis, and the underlying mechanism is largely unknown. Here, we investigate the potential role of the innate immune system in the faltering antibody response following PCV vaccination in RA patients treated with MTX. Phenotypes of circulating granulocytes and monocytes were analyzed in 11 RA patients treated with MTX, 13 RA patients without disease-modifying antirheumatic drug treatment (0DMARD), and 13 healthy controls (HC). Peripheral blood samples were collected before and 7 days after vaccination. In addition, the MTX group was sampled before initiating treatment. Frequencies of granulocyte and monocyte subsets were determined using flow cytometry. Serotype-specific IgG were quantified using a multiplex bead assay, pre- and 4-6 weeks after vaccination. At baseline, no differences in granulocyte and monocyte frequencies were observed between the groups. Within the MTX group, the frequency of basophils increased during treatment and was higher compared to the HC and 0DMARD groups at the prevaccination time point. MTX patients were categorized into responders and nonresponders according to the antibody response. Before initiation of MTX, there were no differences in granulocyte and monocyte frequencies between the two subgroups. However, following 6-12 weeks of MTX treatment, both the frequency and concentration of monocytes were lower in PCV nonresponders compared to responders, and the difference in monocyte frequency remained after vaccination. In conclusion, the suppressive effect of MTX on monocyte concentration and frequency could act as a biomarker to identify nonresponders to PCV vaccination.
Identifiants
pubmed: 35935581
doi: 10.1155/2022/7561661
pmc: PMC9352482
doi:
Substances chimiques
Antirheumatic Agents
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7561661Informations de copyright
Copyright © 2022 Evelina Elmér et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Ann Rheum Dis. 2020 Jan;79(1):39-52
pubmed: 31413005
Nat Rev Immunol. 2017 Jan;17(1):60-75
pubmed: 27916980
Arthritis Rheum. 2002 Sep;46(9):2287-93
pubmed: 12355475
APMIS. 2017 Oct;125(10):863-871
pubmed: 28766758
Cell Rep. 2017 Aug 29;20(9):2251-2261
pubmed: 28854372
Rheumatology (Oxford). 2006 Jan;45(1):106-11
pubmed: 16287919
Viral Immunol. 2020 May;33(4):327-333
pubmed: 32027238
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Cells. 2018 Oct 09;7(10):
pubmed: 30304822
Arthritis Rheum. 2002 Oct;46(10):2578-86
pubmed: 12384915
Arthritis Rheum. 2011 Dec;63(12):3723-32
pubmed: 21834061
Front Immunol. 2017 Dec 11;8:1781
pubmed: 29321780
J Transl Med. 2015 Jan 16;13:2
pubmed: 25592233
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26
pubmed: 24339395
Front Immunol. 2015 Sep 14;6:471
pubmed: 26441976
J Immunol Methods. 2005 Jan;296(1-2):135-47
pubmed: 15680158
Vaccine. 2020 Feb 11;38(7):1778-1786
pubmed: 31911030
Arthritis Rheum. 2012 Mar;64(3):671-7
pubmed: 22006178
Exp Ther Med. 2015 May;9(5):1567-1571
pubmed: 26136859
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
J Rheumatol. 2018 Jun;45(6):733-744
pubmed: 29545454
Sci Rep. 2021 Apr 28;11(1):9199
pubmed: 33911135
Front Immunol. 2021 Jun 10;12:666953
pubmed: 34177905
Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S40-S44
pubmed: 27762189
Ann Rheum Dis. 2017 Sep;76(9):1559-1565
pubmed: 28468794
J Glob Infect Dis. 2011 Jan;3(1):73-8
pubmed: 21572612
Ann Rheum Dis. 2018 Jun;77(6):898-904
pubmed: 29572291
Arthritis Res Ther. 2014 Jan 20;16(1):R17
pubmed: 24444433
Immunity. 2015 Dec 15;43(6):1186-98
pubmed: 26682988
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Nat Rev Rheumatol. 2020 Mar;16(3):145-154
pubmed: 32066940
Arthritis Res Ther. 2012 Jul 27;14(4):R175
pubmed: 22838733
Ann Rheum Dis. 2019 Feb;78(2):282-284
pubmed: 30297326
Rheumatol Int. 2019 Feb;39(2):245-253
pubmed: 30426234
Vaccine. 2011 Mar 16;29(13):2461-73
pubmed: 21256188
Nat Rev Immunol. 2017 Jun;17(6):349-362
pubmed: 28436425
Clin Vaccine Immunol. 2015 Feb;22(2):148-52
pubmed: 25520149
PLoS One. 2012;7(1):e28918
pubmed: 22235253
J Immunol. 2012 Dec 15;189(12):5612-21
pubmed: 23136203